GNI Group Ltd.
Research GNI Group Ltd. (2160.T) on Bullrun: market cap JPY 193.82B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker2160.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyJPY
- Market capJPY 193.82B
- Financial periodFY2025
- RevenueJPY 26.84B
- Revenue growth13.7%
- Net income-JPY 4.24B
- Free cash flow-JPY 3.97B
- Gross margin74.5%
Valuation Snapshot
latest market cap is JPY 193.82B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | JPY 26.84B | -JPY 4.24B | -JPY 3.97B | 74.5% | -80.9 | JPY 21.10B | JPY 5.37B | JPY 50.15B |
| FY2024 | JPY 23.61B | JPY 1.10B | -JPY 4.70B | 76.4% | 21.15 | JPY 10.12B | JPY 7.21B | JPY 36.45B |
| FY2023 | JPY 26.01B | JPY 8.09B | JPY 4.47B | 86.2% | 165.56 | JPY 21.63B | JPY 3.70B | JPY 33.79B |
| FY2022 | JPY 17.42B | JPY 388.83M | -JPY 1.55B | 84.6% | 8.11 | JPY 11.05B | JPY 537.36M | JPY 20.97B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 193.82B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 JPY.
About GNI Group Ltd.
GNI Group Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and sale of pharmaceuticals and biomaterials in Japan, China, and the United States. It operates in two segments, Pharmaceutical Business and Medical Equipment Business. The company offers ETUARY for the treatment of idiopathic pulmonary fibrosis; H-GENIN Crush-Mix for the treatment of bone defects; AltiPly for the treatment of acute and chronic wounds; and orthobiologics products.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is GNI Group Ltd.'s market cap?
GNI Group Ltd.'s market capitalization is JPY 193.82B.
What does GNI Group Ltd. do?
GNI Group Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and sale of pharmaceuticals and biomaterials in Japan, China, and the United States. It operates in two segments, Pharmaceutical Business and Medical Equipment Business. The company offers ETUARY for the treatment of idiopathic pulmonary fibrosis; H-GENIN Crush-Mix for the treatment of bone defects; AltiPly for the treatment of acute and chronic wounds; and orthobiologics products.